Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib

Parkin D.M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002, CA Cancer J Clin, 55, pp. 74-108, (2005)

Llovet J.M., Burroughs A., Bruix J., Hepatocellular carcinoma, Lancet, 362, pp. 1907-1917, (2003)

Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., De Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 4, pp. 378-390, (2008)

So B.J., Bekaii-Saab T., Bloomston M.A., Patel T., Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report, J Hematol Oncol, 1, (2008)

Wang S.X., Byrnes A., Verma S., Pancoast J.R., Rixe O., Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: A case report, Target Oncol, 5, 1, pp. 59-63, (2010)

Sacco R., Bargellini I., Gianluigi G., Bertini M., Bozzi E., Altomare E., Battaglia V., Romano A., Bertoni M., Capria A., Bresci G., Bartolozzi C., Complete response for advanced liver cancer during sorafenib therapy: Case Report, BMC Gastroenterol, 11, (2011)

Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Su Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 1, pp. 25-34, (2009)

Wilhelm S.M., Carter C., Tang L., Et al., BAY 43-9006 exhibits broad spectrumoral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, pp. 7099-7109, (2004)

Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C., Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5, Cancer Res, 66, 24, pp. 11851-11858, (2006)

Abou-Alfa G.K., Schwartz L., Ricci S., Et al., Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, pp. 4293-4300, (2006)

Parkin D.M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002, CA Cancer J Clin, 55, pp. 74-108, (2005)

Llovet J.M., Burroughs A., Bruix J., Hepatocellular carcinoma, Lancet, 362, pp. 1907-1917, (2003)

Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., De Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 4, pp. 378-390, (2008)

So B.J., Bekaii-Saab T., Bloomston M.A., Patel T., Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report, J Hematol Oncol, 1, (2008)

Wang S.X., Byrnes A., Verma S., Pancoast J.R., Rixe O., Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: A case report, Target Oncol, 5, 1, pp. 59-63, (2010)

Sacco R., Bargellini I., Gianluigi G., Bertini M., Bozzi E., Altomare E., Battaglia V., Romano A., Bertoni M., Capria A., Bresci G., Bartolozzi C., Complete response for advanced liver cancer during sorafenib therapy: Case Report, BMC Gastroenterol, 11, (2011)

Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Su Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 1, pp. 25-34, (2009)

Wilhelm S.M., Carter C., Tang L., Et al., BAY 43-9006 exhibits broad spectrumoral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, pp. 7099-7109, (2004)

Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C., Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5, Cancer Res, 66, 24, pp. 11851-11858, (2006)

Abou-Alfa G.K., Schwartz L., Ricci S., Et al., Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, pp. 4293-4300, (2006)